Research
Hormonal
Genetic variants associated with HbA1c levels are linked to an increased risk of coronary artery disease, although this association is attenuated when adjusting for other cardiovascular risk factors.
Higher HbA1c levels are associated with a higher risk of heart disease. While this link is strong, it may be partly explained by other risk factors like cholesterol and weight. Monitoring HbA1c is important for overall cardiovascular health.
ModerateQualifiesMEDIUM confidence
On the other hand, nine genetic variants associated with HbA1c were associated with an OR of 1.53 per 1% HbA1c increase... in the risk of CAD while this effect was non-significant among 30 genetic variants associated with FG per mmol/L.
Why this rating
Significant initial association, but loses significance after multivariate adjustment for lipids and BMI.
Source
Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease
Stephanie Ross et al. · European Heart Journal · 2015
DOI 10.1093/eurheartj/ehv083
Meta-analysisCited 137×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Mendelian randomization analysis confirms a causal relationship between diabetes and an increased risk of coronary artery disease, independent of other risk factors like lipids and BMI.Good
- Genetic variants associated with fasting glucose (FG) levels do not show a significant independent association with coronary artery disease risk in this Mendelian randomization analysis.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →